The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Husain, H.; Velculescu, V.E. Cancer DNA in the Circulation: The Liquid Biopsy. JAMA 2017, 318, 1272–1274. [Google Scholar] [CrossRef] [Green Version]
- Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224ra24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, Y.-Y.; Guo, Q.-R.; Wang, F.-H.; Adhikari, R.; Zhu, Z.-Y.; Zhang, H.-Y.; Zhou, W.-M.; Yu, H.; Li, J.-Q.; Zhang, J.-Y. Cell-Free DNA: Hope and Potential Application in Cancer. Front. Cell Dev. Biol. 2021, 9, 639233. [Google Scholar] [CrossRef] [PubMed]
- Poulet, G.; Massias, J.; Taly, V. Liquid Biopsy: General Concepts. Acta Cytol. 2019, 63, 449–455. [Google Scholar] [CrossRef] [PubMed]
- Ponti, G.; Maccaferri, M.; Mandrioli, M.; Manfredini, M.; Micali, S.; Cotugno, M.; Bianchi, G.; Ozben, T.; Pellacani, G.; Del Prete, C.; et al. Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker. Pathol. Oncol. Res. 2018, 24, 941–945. [Google Scholar] [CrossRef] [PubMed]
- Yao, Y.; Liu, J.; Li, L.; Yuan, Y.; Nan, K.; Wu, X.; Zhang, Z.; Wu, Y.; Li, X.; Zhu, J.; et al. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget 2017, 8, 2130–2140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sant, M.; Bernat-Peguera, A.; Felip, E.; Margelí, M. Role of ctDNA in Breast Cancer. Cancers 2022, 14, 310. [Google Scholar] [CrossRef]
- Malla, M.; Loree, J.M.; Kasi, P.M.; Parikh, A.R. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. J. Clin. Oncol. 2022, 40, 2846–2857. [Google Scholar] [CrossRef]
- Piccioni, D.E.; Achrol, A.S.; Kiedrowski, L.A.; Banks, K.C.; Boucher, N.; Barkhoudarian, G.; Kelly, D.F.; Juarez, T.; Lanman, R.B.; Raymond, V.M.; et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019, 8, CNS34. [Google Scholar] [CrossRef]
- Sato, Y. Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. Explor. Target. Anti-Tumor Ther. 2022, 3, 630–642. [Google Scholar] [CrossRef]
- Pascual, J.; Attard, G.; Bidard, F.-C.; Curigliano, G.; De Mattos-Arruda, L.; Diehn, M.; Italiano, A.; Lindberg, J.; Merker, J.; Montagut, C.; et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2022, 33, 750–768. [Google Scholar] [CrossRef] [PubMed]
- De Mattos-Arruda, L.; Mayor, R.; Ng, C.K.Y.; Weigelt, B.; Martínez-Ricarte, F.; Torrejon, D.; Oliveira, M.; Arias, A.; Raventos, C.; Tang, J.; et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 2015, 6, 8839. [Google Scholar] [CrossRef] [Green Version]
- Perus, L.J.M.; Walsh, L.A. Microenvironmental Heterogeneity in Brain Malignancies. Front. Immunol. 2019, 10, 2294. [Google Scholar] [CrossRef] [PubMed]
- Quattrocchi, C.C.; Errante, Y.; Gaudino, C.; Mallio, C.A.; Giona, A.; Santini, D.; Tonini, G.; Zobel, B.B. Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. J. Neurooncol. 2012, 110, 79–87. [Google Scholar] [CrossRef] [PubMed]
- Rehman, A.U.; Khan, P.; Maurya, S.K.; Siddiqui, J.A.; Santamaria-Barria, J.A.; Batra, S.K.; Nasser, M.W. Liquid biopsies to occult brain metastasis. Mol. Cancer 2022, 21, 113. [Google Scholar] [CrossRef]
- Mansfield, A.; Aubry, M.; Moser, J.; Harrington, S.; Dronca, R.; Park, S.; Dong, H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann. Oncol. 2016, 27, 1953–1958. [Google Scholar] [CrossRef] [PubMed]
- Matsumoto, S.; Takahashi, K.; Iwakawa, R.; Matsuno, Y.; Nakanishi, Y.; Kohno, T.; Shimizu, E.; Yokota, J. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int. J. Cancer 2006, 119, 1491–1494. [Google Scholar] [CrossRef]
- Makino, Y.; Arakawa, Y.; Yoshioka, E.; Shofuda, T.; Minamiguchi, S.; Kawauchi, T.; Tanji, M.; Kanematsu, D.; Nonaka, M.; Okita, Y.; et al. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer 2021, 21, 1025. [Google Scholar] [CrossRef]
- Aran, V.; Heringer, M.; da Mata, P.J.; Kasuki, L.; Miranda, R.L.; Andreiuolo, F.; Chimelli, L.; Filho, P.N.; Gadelha, M.R.; Neto, V.M. Identification of mutant K-RAS in pituitary macroadenoma. Pituitary 2021, 24, 746–753. [Google Scholar] [CrossRef]
- Fares, J.; Kanojia, D.; Rashidi, A.; Ulasov, I.; Lesniak, M.S. Genes that Mediate Metastasis across the Blood-Brain Barrier. Trends Cancer 2020, 6, 660–676. [Google Scholar] [CrossRef]
- Bertolini, F.; Spallanzani, A.; Fontana, A.; Depenni, R.; Luppi, G. Brain metastases: An overview. CNS Oncol. 2015, 4, 37–46. [Google Scholar] [CrossRef] [PubMed]
- Vassella, E.; Kashani, E.; Zens, P.; Kündig, A.; Fung, C.; Scherz, A.; Herrmann, E.; Ermis, E.; Schmid, R.A.; Berezowska, S. Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations. Eur. J. Cancer 2021, 159, 227–236. [Google Scholar] [CrossRef] [PubMed]
- Garcia, J.; Forestier, J.; Dusserre, E.; Wozny, A.-S.; Geiguer, F.; Merle, P.; Tissot, C.; Ferraro-Peyret, C.; Jones, F.S.; Edelstein, D.L.; et al. Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy). Oncotarget 2018, 9, 21122–21131. [Google Scholar] [CrossRef] [Green Version]
- Singh, R.R. Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications. J. Mol. Diagn. 2020, 22, 994–1007. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.; Han, X.; Gao, Y.; Zhao, Q.; Wang, Y.; Jiang, Y.; Liu, S.; Wu, X.; Miao, L. Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review. Onco Targets Ther. 2020, 13, 4359–4364. [Google Scholar] [CrossRef]
- Xu, J.M.; Liu, X.J.; Ge, F.J.; Lin, L.; Wang, Y.; Sharma, M.R.; Liu, Z.-Y.; Tommasi, S.; Paradiso, A. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J. Exp. Clin. Cancer Res. 2014, 33, 104. [Google Scholar] [CrossRef]
- Zhang, M.; Wu, J.; Zhong, W.; Zhao, Z.; Guo, W. Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer. Transl. Cancer Res. 2022, 11, 1245–1254. [Google Scholar] [CrossRef]
- Dong, L.; Wang, S.; Fu, B.; Wang, J. Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection. Sci. Rep. 2018, 8, 9650. [Google Scholar] [CrossRef] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aran, V.; Zogbi, V.M.; Miranda, R.L.; Andreiuolo, F.; Silva Canedo, N.H.; Nazaré, C.V.; Niemeyer Filho, P.; Neto, V.M. The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report. Medicina 2023, 59, 459. https://doi.org/10.3390/medicina59030459
Aran V, Zogbi VM, Miranda RL, Andreiuolo F, Silva Canedo NH, Nazaré CV, Niemeyer Filho P, Neto VM. The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report. Medicina. 2023; 59(3):459. https://doi.org/10.3390/medicina59030459
Chicago/Turabian StyleAran, Veronica, Vinicius Mansur Zogbi, Renan Lyra Miranda, Felipe Andreiuolo, Nathalie Henriques Silva Canedo, Carolina Victor Nazaré, Paulo Niemeyer Filho, and Vivaldo Moura Neto. 2023. "The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report" Medicina 59, no. 3: 459. https://doi.org/10.3390/medicina59030459